Peter DeMuth - Feb 3, 2025 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Role
Chief Scientific Officer
Signature
/s/ Peter DeMuth
Stock symbol
ELTX
Transactions as of
Feb 3, 2025
Transactions value $
$0
Form type
4
Date filed
2/4/2025, 04:11 PM
Previous filing
Dec 18, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELTX Stock Option (Right to Buy) Award $0 +44.4K $0.00 44.4K Feb 3, 2025 Common Stock 44.4K $8.92 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable as to 25% of the options on the first anniversary of the grant date (February 3, 2026), with the remaining options vesting in equal monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.